Statistic, as appropriate. If the distribution of a continuous variable was skewed, median values and interquartile ranges were presented, and the WilcoxonMann-Whitney test was used to detect significant differences. Owing to skewed distributions and the lack of consensus on cut-off points for discriminating abnormalities, leptin, adiponectin, insulin, HOMA-IR, and estradiol concentrations were ca
Mors. Quantitative polymerase chain reaction cut points are shown for high versus low DC-SCRIPT (66.7 versus 33.3 ) [7], for positive versus negative ESR1 (0.2) [14], and for ESR2-low versus -high at the median level of 0.005 (mRNA levels relative to reference gene set). Patients at risk are indicated. DCSCRIPT, dendritic cell-specific transcript; ESR, estrogen receptor; pT1, small tumor without
Nally, stromal cells may have played a role in the induction of DC-SCRIPT in the epithelial tumor cells. In analogy, ESR2 is - apart from breast cancer epithelial tumor cells - also expressed in adjacent infiltrating lymphocytes, fibroblasts, and endothelial cells [3]. Interestingly, in tumors that express relatively high ESR2 mRNA levels and that in general have a higher stromal content, DC-SCRIP
Nally, stromal cells may have played a role in the induction of DC-SCRIPT in the epithelial tumor cells. In analogy, ESR2 is - apart from breast cancer epithelial tumor cells - also expressed in adjacent infiltrating lymphocytes, fibroblasts, and endothelial cells [3]. Interestingly, in tumors that express relatively high ESR2 mRNA levels and that in general have a higher stromal content, DC-SCRIP
Mors. Quantitative polymerase chain reaction cut points are shown for high versus low DC-SCRIPT (66.7 versus 33.3 ) [7], for positive versus negative ESR1 (0.2) [14], and for ESR2-low versus -high at the median level of 0.005 (mRNA levels relative to reference gene set). Patients at risk are indicated. DCSCRIPT, dendritic cell-specific transcript; ESR, estrogen receptor; pT1, small tumor without
Ith DFS, MFS, OS, and PFS, respectively. In multivariable analysis, Cox proportional hazards models for DFS, MFS, OS, and PFS were applied to test DCSCRIPT levels added to models with traditional factors. The proportional hazards assumptions were checked with Schoenfeld residuals. The analyses were stratified if necessary. The models for DFS, MFS, and OS for LNN patients who had not received adjuv
Receptors also modulate response to therapy [8,9], we also assessed, as a secondary aim of this study, the predictive value of DC-SCRIPT by using clinical benefit and progression-free survival (PFS) after first-line tamoxifen for advanced disease as the main endpoints.Materials and methodsPatientsdetermined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [14,16,17]. Follow-up
Receptors also modulate response to therapy [8,9], we also assessed, as a secondary aim of this study, the predictive value of DC-SCRIPT by using clinical benefit and progression-free survival (PFS) after first-line tamoxifen for advanced disease as the main endpoints.Materials and methodsPatientsdetermined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [14,16,17]. Follow-up